Director Chen Chong filed a Form 3 initial statement of beneficial ownership with the SEC on November 13, 2026, disclosing holdings in Ryde Group Ltd (NYSE:RYDE) as of the same date.
1. NVIDIA: Shares Rebound 1.4% as the Senate Banking Chair Seeks Testimony From Huang and Commerce Secretary Lutnick
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed an amended beneficial ownership statement with the SEC on November 13, 2026, reporting a combined holding of 1,389,276 shares of Teradata Corp common stock as of September 30, 2026.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership position in Repay Holdings Corp as of September 30, 2026.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of common stock in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) as of September 30, 2026.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 2,164,817 shares of Texas Capital Bancshares Inc/TX common stock as of September 30, 2026.
Crown Reserve Acquisition Corp. I filed a preliminary proxy statement on November 13, 2026, seeking shareholder approval at an extraordinary general meeting scheduled for December 22, 2026, to extend its business combination deadline and ratify related proposals.
Xenetic Biosciences, Inc. filed a Current Report on Form 8-K on November 13, 2026, announcing third-quarter financial results for the three months ended September 30, 2026, and disclosing strategic business updates including a proposed share exchange transaction with Santersus AG.
Xenetic Biosciences, Inc. filed a Current Report on Form 8-K on November 13, 2026, announcing third-quarter financial results for the period ended September 30, 2026, and providing strategic business updates including details related to a proposed share exchange transaction with Santersus AG.
Tandem Diabetes Care, Inc. filed a Form 8-K on November 13, 2026, disclosing that it received 510(k) clearance from the U.S. Food and Drug Administration on November 12, 2026, for a tubeless configuration of its Tandem Mobi automated insulin delivery system.